Gadolinium-Based Contrast Agents Found to Cause Serious Skin Disorder Called Nephrogenic Systemic Fibrosis or Nephrogenic Fibrosing Dermopathy.
Omniscan (gadodiamide) and other gadolinium containing contrast agents (MRI dyes) are commonly used by physicians in magnetic resonance imaging (MRI) and/or magnetic resonance angiography (MRA). During an MRI or MRA, gadolinium-based contrast agents such as Omniscan are injected into veins of the patient so that the physician can view a clear and detailed picture of a patient’s internal organs, tissues, bones and/or vessels. MRIs and MRAs are typically ordered by physicians in order to detect abnormalities such as tumors, clots, and internal bleeding.
The Omniscan brand gadolinium-based contrast agent (MRI dye) was launched in the U.S. in 1993. However, on June 6, 2006, maker GE Healthcare issued a safety advisory for Omniscan, warning certain physicians that the use of the Omniscan contrast medium (dye) in an MRI or MRA on a patient with pre-existing renal (kidney) issues may lead to that patient developing a very serious medical condition involving the skin called Nephrogenic Systemic Fibrosis (NSF), which is also known as Nephrogenic Fibrosing Dermopathy (NFD) (hereinafter referred to as NSF and NFD). NSF and NFD has thus far been observed almost exclusively in patients with kidney disease or renal dysfunction. NSF and NFD leads to thickened, rough or hard skin, which can sometimes lead to limbs becoming difficult or even impossible to move. In some instances, NSF and NFD can even lead to death. After accumulating numerous reports of NSF and NFD in patients, the United States Food & Drug Administrations (FDA) issued public health advisories in June and December of 2006. Based on the reports the FDA has received thus far, patients typically experienced symptoms of NSF or NFD from 2 days to 18 months after exposure to the gadolinium-based contrast agent (MRI dye) such as Onmiscan.
If you or a loved one have been diagnosed with NSF or NFD after undergoing an MRI or MRA with dye, whether it was Omniscan, or another dye such as Magnevist, MultiHance, OptiMARK or ProHance, you should speak to an experienced pharmaceutical and medical product liability attorney to see if you have a case and to discuss the possibility of bringing a lawsuit to recover for your damages and injuries. The attorney will be able to ascertain if you have a claim for which a lawsuit can be pursued and whether the case and lawsuit can be brought to a successful settlement, verdict, award or other recovery. The experienced lawyer will also be able to advise you on any deadlines for bringing your legal claim for damages. If you or a loved one has experienced a skin disorder called Nephrogenic Systemic Fibrosis (NSF, also known as Nephrogenic Fibrosing Dermopathy, NFD) – sustained as a result of the injection of a gadolinium-based contrast agent such as Omniscan used in MRIs and MRAs (gadodiamide), please contact Ury & Moskow. Although our Gadolinium lawyers are located in Connecticut and Washington, D.C., our drug litigation is national in scope, and our Gadolinium lawyers are prepared to file lawsuits and litigate cases around the country. Please e-mail or call our toll-free number if you would like our lawyers to contact you to discuss your potential claim and possible lawsuit.